3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
NIH
3
INDUSTRY
3
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of the Lung
1
Interventions
Cyclophosphamide
2042
Radiotherapy
1859
Cisplatin
1825
Carboplatin
1533
Gemcitabine
1434
Paclitaxel
1289
Bevacizumab
1270
Docetaxel
1202
pembrolizumab
1198
Oxaliplatin
1160
Capecitabine
1142
Fluorouracil
1061
Dexamethasone
971
Rituximab
919
Nivolumab
908
Magnetic Resonance Spectroscopy
862
Etoposide
839
Doxorubicin
823
Drug Therapy
792
Radiosurgery
776
Irinotecan
775
Cytarabine
736
fludarabine
716
Leucovorin
676
Lenalidomide
608
fludarabine phosphate
564
Temozolomide
552
Radiation
541
Filgrastim
540
Cetuximab
537
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
glembatumumab vedotin
×
Clear all
NCT03473691
2024-12-09
Breast50
University of Virginia
Phase EARLY_PHASE1
Withdrawn
NCT02713828
2019-07-16
PrE0504
PrECOG, LLC.
Phase 1/2
Terminated
13 enrolled
12 charts